DLL4 and neoplasm: To test whether these tumor-suppressive effects are reflected on longevity, both Dll4+/+ and Dll4+/- RT2 mice were treated with PBS or half dose of sEphB4-Alb (5 mg/kg) beginning at 10 weeks of age and continuously monitored for survival benefit estimation.